Piper Sandler analyst Michael Lavery lowered the firm’s price target on Canopy Growth to $1 from $2 and keeps an Underweight rating on the shares. Canopy’s sales trends remain pressured, and PIper’s BioSteel expectations continue to fall, the analyst tells investors in a research note. The firm’s analyst of retail sell-through versus shipments suggests retailers may have over 200 days of inventory, a likely drag on near-term shipments.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CGC:
- Canopy Growth upgraded to Market Perform from Underperform at BMO Capital
- Bipartisan lawmakers reintroduce Safe Banking Act for cannabis businesses
- Rising High: Exclusive talk with biotech company PharmAla
- Booker says lawmakers to revive cannabis banking bill, Marijuana Moment says
- Here’s What You Missed in Cannabis This Week